Machine learning predictions based on historical earnings data and price patterns
1-Day Prediction
-4.51%
$6.45
100% positive prob.
5-Day Prediction
+12.92%
$7.63
100% positive prob.
20-Day Prediction
+2.62%
$6.94
95% positive prob.
SEC 8-K filings with transcript text
Mar 4, 2026 · 100% conf.
1D
-4.51%
$6.45
Act: -18.64%
5D
+12.92%
$7.63
20D
+2.62%
$6.94
8-K
false000183559700018355972026-03-042026-03-04
Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934
Date of Report (Date of earliest event reported): March 04, 2026
PepGen Inc. (Exact name of Registrant as Specified in Its Charter)
Delaware
001-41374
85-3819886
(State or Other Jurisdiction of Incorporation)
(Commission File Number)
(IRS Employer Identification No.)
321 Harrison Avenue 8th Floor
Boston, Massachusetts
02118
(Address of Principal Executive Offices)
(Zip Code)
Registrant’s Telephone Number, Including Area Code: (781) 797-0979
(Former Name or Former Address, if Changed Since Last Report)
Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions: ☐Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425) ☐Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12) ☐Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b)) ☐Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c)) Securities registered pursuant to Section 12(b) of the Act:
Title of each class
Trading Symbol(s)
Name of each exchange on which registered
Common stock, par value $0.0001 per share
Nasdaq Global Select Market
Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§ 230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§ 240.12b-2 of this chapter). Emerging growth company ☒ If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐
Item 2.02 Results of Operations and Financial Condition. On March 4, 2026, PepGen Inc. (the "Company") announced its financial results for the year ended December 31, 2025 and issued a press release titled "PepGen Reports Fourth Quarter and Year-End 2025 Financial Results and Recent Corporate Highlights". A copy of the press release is furnished as Exhibit 99.1.
The information provided in this Current Report on Form 8-K (this “Form 8-K”), including Exhibit 99.1, shall not be deemed “filed” for purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the “Exchange Act”), or otherwise subject to the liabilities of that section, nor shall it be deemed incorporated by reference into any of the Company’s filings under the Securities Act of 1933, as amended (the “Securities Act”), or the Exchange Act, except as expressly set forth by specific reference in such filing. Item 8.01 Other Events. On March 4, 2026, the Company announced that it received a partial clinical hold notice from the U.S. Food and Drug Administration on the FREEDOM2-DM1 Phase 2 multiple ascending dose ("MAD"), randomized, placebo-controlled clinical trial of PGN-EDODM1 in patients with myotonic dystrophy type 1 ("DM1"). A copy of the press release issued in connection with the announcement is attached as Exhibit 99.2 to this form 8-K and incorporated herein by reference. Item 9.01 Financial Statements and Exhibits. (d) Exhibits
Exhibit Number
Description
99.1
Press Release issued by PepGen Inc. on March 4, 2026 titled "PepGen Reports Fourth Quarter and Year-End 2025 Financial Results and Recent Corporate Highlights"
99.2
Press Release issued by PepGen Inc. on March 4, 2026 titled "PepGen Announces Regulatory Updates on FREEDOM2"
104
Cover Page Interactive Data File (embedded within Inline XBRL document)
Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.
PepGen Inc.
Date:
March 4, 2026
By:
/s/ Noel Donnelly
Noel Donnelly, Chief Financial Officer
Nov 12, 2025
8-K
0001835597false00018355972025-11-122025-11-12
Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934
Date of Report (Date of earliest event reported): November 12, 2025
PepGen Inc. (Exact name of Registrant as Specified in Its Charter)
Delaware
001-41374
85-3819886
(State or Other Jurisdiction of Incorporation)
(Commission File Number)
(IRS Employer Identification No.)
321 Harrison Avenue 8th Floor
Boston, Massachusetts
02118
(Address of Principal Executive Offices)
(Zip Code)
Registrant’s Telephone Number, Including Area Code: (781) 797-0979
(Former Name or Former Address, if Changed Since Last Report)
Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions: ☐Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425) ☐Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12) ☐Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b)) ☐Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c)) Securities registered pursuant to Section 12(b) of the Act:
Title of each class
Trading Symbol(s)
Name of each exchange on which registered
Common stock, par value $0.0001 per share
Nasdaq Global Select Market
Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§ 230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§ 240.12b-2 of this chapter). Emerging growth company ☒ If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐
Item 2.02 Results of Operations and Financial Condition. On November 12, 2025, PepGen Inc. announced its financial results for the quarter ended September 30, 2025 and other business updates. A copy of the press release is furnished as Exhibit 99.1. Item 9.01 Financial Statements and Exhibits. d) Exhibits
The following exhibit relating to Item 2.02 of this Form 8-K shall be deemed to be furnished and not filed:
Exhibit Number
Description
99.1
Press release issued by PepGen Inc. on November 12, 2025
104
Cover Page Interactive Data File (embedded within Inline XBRL document)
Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.
Date:
November 12, 2025
By:
/s/ Noel Donnelly
Noel Donnelly, Chief Financial Officer
Aug 7, 2025
8-K
false000183559700018355972025-08-072025-08-07
Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934
Date of Report (Date of earliest event reported): August 07, 2025
PepGen Inc. (Exact name of Registrant as Specified in Its Charter)
Delaware
001-41374
85-3819886
(State or Other Jurisdiction of Incorporation)
(Commission File Number)
(IRS Employer Identification No.)
321 Harrison Avenue 8th Floor
Boston, Massachusetts
02118
(Address of Principal Executive Offices)
(Zip Code)
Registrant’s Telephone Number, Including Area Code: (781) 797-0979
(Former Name or Former Address, if Changed Since Last Report)
Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions: ☐Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425) ☐Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12) ☐Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b)) ☐Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c)) Securities registered pursuant to Section 12(b) of the Act:
Title of each class
Trading Symbol(s)
Name of each exchange on which registered
Common stock, par value $0.0001 per share
Nasdaq Global Select Market
Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§ 230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§ 240.12b-2 of this chapter). Emerging growth company ☒ If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐
Item 2.02 Results of Operations and Financial Condition. On August 7, 2025, PepGen Inc. announced its financial results for the quarter ended June 30, 2025 and other business updates. A copy of the press release is furnished as Exhibit 99.1. Item 9.01 Financial Statements and Exhibits. d) Exhibits
The following exhibit relating to Item 2.02 of this Form 8-K shall be deemed to be furnished and not filed:
Exhibit Number
Description
99.1
Press release issued by PepGen Inc. on August 7, 2025
104
Cover Page Interactive Data File (embedded within Inline XBRL document)
Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.
Date:
August 7, 2025
By:
/s/ Noel Donnelly
Noel Donnelly, Chief Financial Officer
This page provides PepGen Inc. (PEPG) earnings call transcripts from SEC 8-K filings along with AI-powered predictions for post-earnings price movements. Our machine learning models analyze historical earnings data, pre-earnings price patterns, volume changes, and volatility to predict 1-day, 5-day, and 20-day returns after each earnings release.
Earnings transcripts are sourced directly from SEC EDGAR filings. Predictions are generated using gradient boosting models trained on PEPG's historical earnings reactions. All predicted returns are shown as percentages, and predicted prices are calculated from the closing price at the time of prediction. Past performance does not guarantee future results.